Research programme: PKC theta antagonists - HotSpot Therapeutics
Alternative Names: Protein kinase C theta antagonists - HotSpot TherapeuticsLatest Information Update: 28 Sep 2023
At a glance
- Originator HotSpot Therapeutics
- Class Small molecules
- Mechanism of Action Protein kinase C theta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders